重点通报！福茂集团掌舵人赵安吉车祸离世，享年50岁

福茂集团掌舵人赵安吉车祸离世，享年50岁

上海2024年2月13日讯 据福茂集团及赵氏家族发布的讣告，福茂集团董事长兼首席执行官赵安吉女士于2月12日凌晨因车祸不幸离世，享年50岁。

赵安吉女士于1974年出生于上海，1996年毕业于美国哈佛大学商学院，获工商管理硕士学位。1994年至1996年，她在史密斯·邦尼（Smith Barney，现属摩根士丹利集团）合并与并购部门任职。1996年加入福茂集团，历任多个重要职务，于2019年升任董事长兼首席执行官。

在赵安吉女士的带领下，福茂集团业务迅速发展，成为全球领先的航运和物流企业之一。她卓越的领导才能和商业智慧获得了业界的广泛认可，曾多次荣获殊荣，包括“中国最具影响力的商界女性”等。

赵安吉女士的突然离世，对福茂集团和全球航运物流行业都是一个重大损失。她的家人、朋友和同事们都对她的离去深表悲痛。

以下是对赵安吉女士生平的几点补充：

• 赵安吉女士是福茂集团创始人赵正东的长女。她从小就表现出极高的商业天赋，在父亲的悉心栽培下，逐渐成长为一名优秀的企业家。
• 赵安吉女士是一位工作狂，她经常加班到深夜，甚至周末也不休息。她对工作充满热情，总是尽自己最大的努力把事情做好。
• 赵安吉女士是一位慈善家，她积极参与各项公益事业，为社会捐赠了大量资金。她热心帮助他人，是一位受人尊敬的社会人士。

赵安吉女士的去世，不仅是福茂集团的损失，也是中国商界的损失。我们将永远缅怀她。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.